Endometriosis is a painful chronic inflammatory disorder impacting 10-15% of women of reproductive age. Endometrial lesions are major drivers of inflammation, leading to disruption of hormone regulation and immune function. In patients with endometriosis, the levels of specialized pro-resolving mediators (SPMs; specifically, LXA4) in their endometrial tissues are reduced. Given the link between endometriosis and chronic unresolved inflammation, assessing the impact of SPMs and pro-resolving therapies is a promising area of research.
In this document, we describe the scientific rationale for inflammation management in endometriosis and summarize emerging data in preclinical models suggesting that administering specific SPMs may have the potential to attenuate multiple factors attributable to the development of endometriosis.
